Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows ...

Vodafone Idea faced a major outage in Delhi, Mumbai, Pune and NCR in the early hours of April 18. Services have now been ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance. Currently trading with a volume of 624,788 ...

David Ricks is the CEO of Eli Lilly, the most valuable drugmaker in the world by market capitalization. Lilly is on the path to become the first trillion-dollar pharma company, fueled by the ...

Apple (AAPL) shares also rose, helping the iPhone maker reclaim its title as the world's most valuable company by market ... (AZN), Pfizer (PFE), Eli Lilly (LLY), Novo Nordisk (NVO), Johnson ...

Eli Lilly is a veteran of the industry. It has been around -- and thrived -- for decades across multiple administrations, changes in regulatory regimes, recessions, and more. No company can ...